Hepatitis B infection: current concepts and future challenges

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic hepatitis B (CHB) is a significant global health issue impacting over 350 million individuals.
• The chronicity of hepatitis B virus (HBV) infection is inversely related to the age of initial exposure.
• Understanding CHB's natural history is crucial for effective disease management and preventing severe outcomes like cirrhosis and liver cancer.

Purpose of the Study:

• To explore the immunological underpinnings of chronic hepatitis B (CHB) and viral persistence.
• To identify factors contributing to poor treatment responses and the inability of current therapies to achieve sustained viral clearance.
• To highlight the need for a comprehensive understanding of CHB's immunological phases and molecular mechanisms for developing novel therapeutic strategies.

Main Methods:

• Review of current literature on CHB pathophysiology and treatment outcomes.
• Analysis of immunological defects in chronic HBV infection, including innate and adaptive immune responses.
• Examination of the liver microenvironment's role in viral persistence and immune tolerance.

Main Results:

• Current antiviral therapies for CHB primarily focus on suppressing HBV DNA levels but often fail to achieve sustained off-treatment responses or complete viral eradication.
• Impaired host immune responses, characterized by defective innate antiviral functions, T-cell exhaustion, and a tolerogenic liver environment, contribute significantly to poor clinical outcomes.
• A deeper understanding of CHB's immunological phases, triggers for liver flares, and mechanisms of viral persistence is essential for advancing treatment.

Conclusions:

• Achieving sustained viral clearance in CHB likely requires a dual approach combining host immune system enhancement through immunotherapy with effective viral load suppression.
• Future therapeutic strategies must address both the virus and the host's immune response to overcome the limitations of current treatments.
• Further research into the complex interplay between HBV and the immune system is critical for developing curative therapies for chronic hepatitis B.